We are a team of people passionate about improving the lives of cancer patients with the development of our platform to predict response to immunotherapy.
Immunotherapies work by activating a person's own immune system to fight disease. Patients can achieve durable responses, providing great promise for these therapies against cancer. Despite a significant increase in the number of available immunotherapies, only 1 in 5 patients receiving immunotherapy respond and many who may respond are not eligible for immunotherapy due to a lack of accurate predictive biomarkers. At Elephas, we’re seeking to change this paradigm.
Our team is developing an oncology platform to predict response to immunotherapy that utilizes live tissue from a biopsy. The tumor microenvironment is complex in nature. The interplay of genes, proteins, tumor cells, stroma, and immune cells is too complex for RNA or single-biomarker approaches to capture effectively. That's why we've developed a unique approach that protects the live, native tumor microenvironment. Our innovative technology measures immunotherapy response from a live tumor over time. The platform is tumor-agnostic and designed to evaluate treatment across indications and immunotherapies. Making us uniquely positioned to predict response to immunotherapy within 72 hours of biopsy, before treatment begins.